The R1441C mutation of LRRK2 disrupts GTP hydrolysis
- 8 June 2007
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 357 (3), 668-671
- https://doi.org/10.1016/j.bbrc.2007.04.006
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute on Aging
This publication has 14 references indexed in Scilit:
- Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1Journal of Neurochemistry, 2007
- Kinase activity of mutant LRRK2 mediates neuronal toxicityNature Neuroscience, 2006
- Kinase activity is required for the toxic effects of mutant LRRK2/dardarinNeurobiology of Disease, 2006
- LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domainCellular Signalling, 2006
- Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activityProceedings of the National Academy of Sciences of the United States of America, 2005
- A common LRRK2 mutation in idiopathic Parkinson's diseaseThe Lancet, 2005
- Genetic screening for a single common LRRK2 mutation in familial Parkinson's diseaseThe Lancet, 2005
- Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's DiseaseNeuron, 2004
- Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic PathologyNeuron, 2004
- Roc, a Ras/GTPase domain in complex proteinsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2003